The blood test distributor agrees to pay $ 195,000 to settle allegations that it violated the FCA. The U.S. Department of Health and Human Services Office of Inspector General (OIG) lately conducted an investigation into False Claims Act (FCA) violations by GlycoMark, Inc. The OIG alleges that GlycoMark encouraged providers to submit claims for its hyperglycemia […]
The post GlycoMark Settles False Claims Act Allegations appeared first on AAPC Knowledge Center.